Golden cross already happened. Most investors continually

New Post Public Reply Private Reply Replies (0) Message Board
joey68
933
Golden cross already happened. Most investors continually use the wrong data:

http://stockcharts.com/h-sc/ui?s=OWCP&p=D...6770197197

EMA lines are more accurate (in my opinion). I wont go too much in detail about it because a quick google search will reveal all mysteries, but in short.. I use the following two EMA lines:

fast EMA line: 13
slow EMA line: 48.5


I cringe when people use 50 and 200 SMA lines. They are OLD, BORING, and SLOWW!!!!

How do you think I knew OWCP was going to skyrocket?

OWCP to $1 soon

Quote:
Exponential moving averages (EMAs), which weigh most recent prices heavier than earlier prices , perform better overall than SMAs, which weight all prices in the timeframe equally.


Not investment advice

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 42

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 309

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 84

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmmi Receives Extension to Comply with NASDAQ Requirements

Updated Category News Views 64

Farmmi Secures NASDAQ Compliance Extension Farmmi, Inc. (NASDAQ: FAMI), a supplier of agricultural products, has been granted a 180-day extension by NASDAQ to meet its crucial minimum bid price requirement. This extension allows the company until the spring of 2025 to elevate its ordinary share bid price to at least $1.00 for at least ten consecutive business days. The...

Continue Reading
The Neurotechnology Surge: $57B Market by 2034

Updated Category News Views 16

Neurotechnology: The Rising Giant Elbows on the table, let's chew the fat about neurotechnology. The market, dizzyingly projected to soar past USD 57 billion by 2034, is on an explosive trajectory. Folk wiser than us predict an annual growth rate hanging around 14%. This ain't just whispers in coffee shops; it's cold, hard data from DelveInsight’s Market Insights...

Continue Reading
Reviva Pharmaceuticals' New Phase 3 Study for Schizophrenia Drug

Updated Category News Views 99

Reviva Pharmaceuticals' Regulatory Update Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has recently provided an update regarding their journey with brilaroxazine, a novel drug aimed at treating schizophrenia. This news comes after a pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). About Brilaroxazine Brilaroxazine is an innovative...

Continue Reading
Lowe's Reports Strong Earnings Amid Strategic Acquisitions

Updated Category News Views 117

Strong Q2 Earnings Surprise Lowe’s Companies Inc (NYSE: LOW) experienced better-than-expected second quarter earnings, bringing a burst of optimism for investors. The home improvement giant saw its stock increase by approximately 2% shortly after announcing its Q2 financial results. Having recorded solid performance through the quarter, Lowe’s exceeded analysts'...

Continue Reading
Invideo and Kling AI Unite for Game-Changing Visuals

Updated Category News Views 153

Invideo and Kling AI Collaborate to Redefine Video Editing Invideo has recently partnered with Kling AI to introduce an exciting tool known as VFX House. This innovative feature empowers creators with studio-level control for their video projects, offering enhanced capabilities for both marketing and editorial work. Unlocking New Possibilities with VFX House The...

Continue Reading